Lexaria Bioscience Corp Cash Flow Conversion Efficiency
Lexaria Bioscience Corp cash flow conversion efficiency. Based on the latest financial reports, Lexaria Bioscience Corp (LEXX) has a cash flow conversion efficiency ratio of -0.376x as of May 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.64 Million) by net assets ($4.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lexaria Bioscience Corp (2005–2025)
Cash flow conversion efficiency of Lexaria Bioscience Corp from 2005 to 2025. This chart illustrates how Lexaria Bioscience Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LEXX live share price for real-time trading data and today's change.
Lexaria Bioscience Corp Cash Flow Conversion Ratio Explained
Lexaria Bioscience Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lexaria Bioscience Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexaria Bioscience Corp ranked by their cash flow conversion efficiency. Also see Lexaria Bioscience Corp market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perpetual Resources Ltd
AU:PEC
|
-0.164x |
|
Minrex Resources Ltd
AU:MRR
|
-0.060x |
|
LCL Resources Ltd
AU:LCL
|
-0.033x |
|
Imperial Pacific Ltd
AU:IPC
|
0.024x |
|
Modern Internasional Tbk
JK:MDRN
|
0.057x |
|
Northeast Electric Development Company Limited
F:NE4H
|
0.009x |
|
Tokyo Plast International Limited
NSE:TOKYOPLAST
|
-0.028x |
|
Humax Holdings Co. Ltd
KQ:028080
|
0.092x |
Annual Cash Flow Conversion Efficiency for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Lexaria Bioscience Corp from 2005 to 2025. Review free cash flow generation of Lexaria Bioscience Corp to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $2.60 Million | $-10.45 Million | -4.015x | -520.13% |
| 2024-08-31 | $7.66 Million | $-4.96 Million | -0.647x | +70.49% |
| 2023-08-31 | $2.68 Million | $-5.88 Million | -2.194x | -243.26% |
| 2022-08-31 | $7.63 Million | $-4.88 Million | -0.639x | -109.32% |
| 2021-08-31 | $13.06 Million | $-3.99 Million | -0.305x | +71.05% |
| 2020-08-31 | $2.48 Million | $-2.62 Million | -1.055x | +12.57% |
| 2019-08-31 | $2.49 Million | $-3.01 Million | -1.207x | -14.45% |
| 2018-08-31 | $2.39 Million | $-2.52 Million | -1.054x | -88.77% |
| 2017-08-31 | $2.77 Million | $-1.55 Million | -0.559x | +92.58% |
| 2016-08-31 | $87.76K | $-660.86K | -7.531x | -229.41% |
| 2015-08-31 | $656.60K | $-1.50 Million | -2.286x | -1594.78% |
| 2014-08-31 | $2.10 Million | $321.00K | 0.153x | 0.00% |
| 2013-08-31 | $2.10 Million | $321.00K | 0.153x | +6.02% |
| 2012-08-31 | $2.23 Million | $321.00K | 0.144x | +182.41% |
| 2011-08-31 | $2.66 Million | $135.94K | 0.051x | +11.09% |
| 2010-08-31 | $2.39 Million | $109.84K | 0.046x | +130.70% |
| 2009-08-31 | $2.21 Million | $-330.34K | -0.150x | -913.10% |
| 2008-08-31 | $2.46 Million | $-36.40K | -0.015x | -272.88% |
| 2007-08-31 | $3.39 Million | $29.04K | 0.009x | +102.76% |
| 2006-08-31 | $704.55K | $-218.56K | -0.310x | -120.33% |
| 2005-08-31 | $1.09 Million | $-153.38K | -0.141x | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more